Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01278615 · ClinicalTrials.gov registry record · Phase 2
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01278615: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01278615 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01278615, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01278615
The ClinicalTrials.gov registry entry for NCT01278615 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01278615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01278615 about?
NCT01278615 is a clinical study titled "Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma". This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01278615?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2010-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01278615?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT01278615?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.